Good Lifestyle

Covid-19 vaccines available in the United States are very effective because they trigger an immune response to produce antibodies that can protect against the virus. Of course, each vaccine is manufactured differently, which means that everyone can have a different effect on the body, work differently against new variants and offer different levels of protection over time. But a new study found that a current vaccine in particular can produce considerably more antibodies than others.

RELATED:If you have Pfizer, this new study is a "clock call", says Biden help.

The results come from a study published on August 16 inJAMA internal medicine, which analyzed the vaccine reaction in 954 health care workers of Johns Hopkins. The results revealed that those who received theVACCINE MODERNA ARNA Developed more SPIKE IgG antibodies than those who have received the vaccine against Pfizer 14 days or more after their second dose.

The authors also noted that, in addition to a robust antibody response, the participants who have received the Moderna vaccine were significantly more likely to report "clinically significant symptoms" than the authors of the study have defined as Fatigue, fever and chills. The results showed that even if only 43% reported any kind of symptoms after their second dose, those who received Moderna were 83% more likely toReport clinically significant symptoms After their first dose that the recipients of Pfizer and 150 more likely after the second dose.

RELATED:If you have this vaccine, you can be more protected against Delta.

The authors of the study concluded that there could be a correlation between the increased probability of symptoms and the increase in antibodies observed in the beneficiaries of the Moderna vaccine. But they warned that recovering it from COVID-19 could affect the results and some are concerned about being concerned about their shots could not have taken with their immune system.

"These vaccines can generate greater local and systemic reactions in people with previous SARS-COV-2 infection," he wrote. "If the symptoms that follow the vaccination are associated with efficiency is unknown and, therefore, anxiety can occur in people who have not developed reaction after vaccination."

In any event, the authors of the study concluded that the Moderna vaccine was more likely to produce a stronger immune response and more antibodies. "IGG Spike antibody measures were higher in the health workers who have received the Moderna vaccine, had an infection prior to SARS-COV-2 and reported clinically significant reactions," wrote the authors of the study. "The role of higher antibody levels in the prevention of COVID-19 and the provision of sustainable immunity remains unknown, however. Overall, the results suggest that regardless of vaccine reactions or previous infections of SARS. -COV-2, the Spike anti-rocker vaccine will provide a robust response antibody. "

RELATED:For more information up to date, sign up for our daily newsletter.

Other recent research has begun to give scientists a better understanding of how antibodies can helpDetermine how much someone is protected of the coronavirus novel. During a press briefing held by the White House Covid Response Team on August 18,Anthony Fauci, MD, head of the White House Covid, cited a study published on a pre-expression server on August 10. He explained that the researchers werelooking for "correlates of immunity" In the blood of vaccinated people and found specific proteins that can neutralize the virus.

The study concluded that higher levels of these antibodies in patients mean increased vaccine efficiency. The results emphasized the wealthy argument that the general public would need crissonsRise antibody levels To protect against very contagious variants such as Delta, NPR reported.

RELATED:If you did this before your vaccine against Pfizer, you may be more protected.